Skip to content
Teva Pharmaceuticals
-
Teva Pharmaceuticals bids US$125M for BioXcel’s neuroscience assets
Under the agreement, Teva would acquire worldwide rights to Igalmi (dexmedetomidine) sublingual film, a prescription medicine, as well as BXCL501, an investigational therapy.
-
Teva announces 250 layoffs at Israel plant after failed sale
The move comes as Teva advances plans to divest its API unit, Teva Active Pharmaceutical Ingredients (TAPI), a process first announced in January 2024.
-
-
Teva secures USD400M from Blackstone to advance bowel disease drug development
The Israeli pharmaceutical company will receive the funding over four years to support ongoing trials of the anti-TL1A antibody, which Teva is co-developing with Sanofi.